Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 6991
- Registration Number
- NCT01897532
- Locations
- 🇺🇸
DM Clinical Research, Tomball, Texas, United States
🇺🇸Pioneer Research Solutions, Inc., Sugar Land, Texas, United States
🇦🇷Prevencion Cardiovascular Salta, Salta, Salta, Argentina
Pradaxa Study in Non-valvular Atrial Fibrillation Patients With Severely Impaired Renal Function
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2016-11-30
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 63
- Registration Number
- NCT01896297
- Locations
- 🇺🇸
1160.173.026 Boehringer Ingelheim Investigational Site, St. Louis, Missouri, United States
🇺🇸1160.173.011 Boehringer Ingelheim Investigational Site, Fort Worth, Texas, United States
🇺🇸1160.173.019 Boehringer Ingelheim Investigational Site, St. Louis, Missouri, United States
Open Label Study Comparing Efficacy and Safety of Dabigatran Etexilate to Standard of Care in Paediatric Patients With Venous Thromboembolism (VTE)
- Conditions
- Venous Thromboembolism
- Interventions
- Drug: standard of care
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 267
- Registration Number
- NCT01895777
- Locations
- 🇦🇷
Hospital General de Niños Pedro de Elizalde, Caba, Argentina
🇧🇪UZ Leuven, Leuven, Belgium
🇦🇹AKH - Medical University of Vienna, Wien, Austria
Safety and Tolerability of BI 409306 in Patients With Schizophrenia
- First Posted Date
- 2013-07-04
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 40
- Registration Number
- NCT01892384
- Locations
- 🇺🇸
1289.18.1 Boehringer Ingelheim Investigational Site, Austin, Texas, United States
Relative Bioavailability of Ibuprofen From a Single Fixed Dose Combination Tablet of Ibuprofen and Caffeine Compared to Single Tablets of Ibuprofen and Ibuprofen Lysinate
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2013-06-17
- Last Posted Date
- 2016-11-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT01879371
- Locations
- 🇩🇪
1335.2.1 Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 187004 in Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2013-06-11
- Last Posted Date
- 2016-01-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 71
- Registration Number
- NCT01874483
- Locations
- 🇩🇪
1307.2.1 Boehringer Ingelheim Investigational Site, Neuss, Germany
Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls
- Conditions
- Diabetes Mellitus, Type 2Healthy
- Interventions
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 39
- Registration Number
- NCT01867307
- Locations
- 🇺🇸
Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States
Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2014-01-23
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT01858961
- Locations
- 🇦🇺
1241.37.61002 Boehringer Ingelheim Investigational Site, Westmead, New South Wales, Australia
🇸🇪1241.37.46001 Boehringer Ingelheim Investigational Site, Stockholm, Sweden
🇪🇸1241.37.34003 Boehringer Ingelheim Investigational Site, Madrid, Spain
LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy
- First Posted Date
- 2013-05-17
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 340
- Registration Number
- NCT01856478
- Locations
- 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, China
🇨🇳Beijing Chao-Yang Hospital, Beijing, China
🇨🇳Cancer Hospital of Chinese Academy of Medical Science, Beijing, China
An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)
- First Posted Date
- 2013-05-15
- Last Posted Date
- 2025-04-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 481
- Registration Number
- NCT01853826
- Locations
- 🇮🇹
A.O. Univ. Policlinico "Paolo Giaccone", Palermo, Italy
🇨🇿University Hospital Ostrava, Ostrava, Czechia
🇮🇱Rabin Medical Center Beilinson, Petah Tikva, Israel